BRAF and melanoma: Along the same line, Polκ was very recently shown to be upregulated in melanoma, lung, and breast cancer cells treated with an inhibitor of the BRAF oncogene, contributing to drug resistance, probably by a non-mutagenic fashion [88], which may probably be through regulation of the DDR.